Moors & Cabot, Inc. Crispr Therapeutics Ag Transaction History

Moors & Cabot, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$60.67 - $89.12 $37,615 - $55,254	-620 Reduced 17.3%	2,963 $201,000
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $138,375 - $258,620	3,583 New	3,583 $224,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $142,633 - $226,475	-2,035 Closed	0 $0
Q3 2021 Dec 08, 2021	BUY	$110.2 - $156.64 $224,257 - $318,762	2,035 New	2,035 $228,000
Q3 2021 Nov 05, 2021	SELL	$110.2 - $156.64 $207,727 - $295,266	-1,885 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$100.84 - $161.89 $14,621 - $23,474	145 Added 8.33%	1,885 $305,000
Q1 2021 May 12, 2021	BUY	$110.72 - $210.04 $192,652 - $365,469	1,740 New	1,740 $212,000

499

56.8M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.